Serine Proteases in Gastrointestinal Function and Irritable Bowel Syndrome (IBS)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-02-28

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The proposed pilot project for this seed grant focuses on the role of intestinal serine-proteases in the pathogenesis of diarrhea-predominant IBS (D-IBS). In this study we will further assess serine-protease activity in patients with D-IBS and also explore a possible mechanism by which these proteases can lead to alterations in intestinal physiology and symptoms in these patients.

The general hypotheses for the proposed research are that (A) the levels of fecal serine-protease in patients with D-IBS are abnormally increased (B) this abnormal serine-protease activity leads to/is associated with an abnormal increase in intestinal permeability and therefore enables (C) chronic stimulation and activation of the mucosal immune system in these patients. In addition, it is aim to determine whither periodontal inflammation is associated with intestinal permeability and serine protease activity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Role of Intestinal Inflammation in Irritable Bowel Syndrome (IBS)

NCT01072903

Inflammation Colon, Irritable Colonic Diseases, Functional +1 more

COMPLETED

Altered Faecal Protease Activity in Irritable Bowel Syndrome Patients in China

NCT01060527

Irritable Bowel Syndrome

UNKNOWN

Phenotyping IBS: Perceptions and Modulations of Visceral Sensations

NCT02693730

Irritable Bowel Syndrome Ulcerative Colitis Inflammatory Bowel Disease

COMPLETED

Genetic Determinism of Epithelial Barrier Defects in Irritable Bowel Syndrome

NCT02841878

Irritable Bowel Syndrome (IBS)

WITHDRAWN NA

"Functional Bowel Disorder. Investigation in General Practice"

NCT01153295

Irritable Bowel Syndrome

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colon, Irritable

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IBS

Subjects with IBS-D

No interventions assigned to this group

Healthy

Healthy Subjects

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Any sex, race, or ethnicity.
* At least 18 years of age (no upper age limit).
* D-IBS patients must meet Rome III criteria for IBS and must have been evaluated by a physician to exclude other diseases that could explain the symptoms. For the latter, patients self statement is acceptable (no official document is required).
* Participation in Dr. Whitehead's 'heterogeneity of IBS' and/or Dr. Ringel's 'intestinal inflammation in patients with D-IBS' research study.

Exclusion Criteria

* Healthy controls must have no significant or recurring gastrointestinal symptoms.
* Patients and healthy controls should not have a serious, unstable medical condition.
* Patients and healthy controls must have had no gastrointestinal tract surgery other than appendectomy or cholecystectomy.
* Patients and healthy controls must not be pregnant (by self-report). Pregnant women will not be allowed to participate as pregnancy can affect gastrointestinal symptoms.
* Patients and healthy controls must not have a history of inflammatory bowel disease, celiac disease, or other diagnosis that could explain chronic or recurring bowel symptoms in IBS patients or controls.
* Patients and healthy controls should have no history of lactose malabsorption (by self-report).
* Patients and healthy controls should have no history of clinical symptoms of acute infections during the last 8 weeks prior to enrolment in the study.
* Patients and healthy controls should have no history of anti-inflammatory agents including aspirin, non-aspirin, non-steroid anti-inflammatory (NSAID) or steroids in the last four weeks prior to study enrollment.
* Patients should not intentionally consume probiotics or undergo antibiotic treatment during the last 4 weeks prior to enrolment in the study. If the subject consumed any of these medications, a washout period of 4 weeks will be required).
* Patients must have no history of fainting or light headedness during periods of fasting.
* Patients must not have diabetes mellitus, or any similar conditions, that would cause an adverse reaction to the sugar drink.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes